New Market - August 24, 2026
Genetic Analysis enters Australian market
Norwegian microbiome diagnostics company Genetic Analysis has placed its GA-map Dysbiosis Test at the Centre for Digestive Diseases (CDD) in Sydney – the company's first placement in Australia and a new milestone in its international expansion.
Biotech Business - August 21, 2026
Hansa Biopharma prepares for US listing
The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.
MedTech Business - August 21, 2026
Implantica receives FDA approval for RefluxStop
The FDA has granted Premarket Approval (PMA) for RefluxStop, the company’s implant-based treatment for gastroesophageal reflux disease (GERD).
Agreement - August 20, 2026
SynAct signs term sheet for Brazilian dengue partnership
SynAct Pharma has signed a term sheet with Brazilian pharmaceutical company Hipolabor to co-develop and commercialize resomelagon for dengue and other viral infections in Brazil.
New Market - August 18, 2026
NextCell selected as the only Swedish company in the EU-Japan Biotech Business Mission 2026
In parallel, the company is strengthening its local presence in Hong Kong by establishing an office and becoming a member of the Hong Kong-Shenzhen Innovation and Technology Park (HSITP).
New Market - July 16, 2026
Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management
The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.